title: Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
abstract: (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a new dopamine agonist which is capable of producing a sustained response in parkinsonian patients with "on-off" fluctuations when given as a continuous infusion either nasogastrically or intravenously. These data suggest that a sustained release formulation of PHNO may provide a significant, new treatment for patients with "on-off" fluctuations.
authors.affiliation: Institute of Neurology, Queen Square, London, United Kingdom.
authors.forename: R J
authors.initials: RJ
authors.lastname: Coleman
authors.forename: N P
authors.initials: NP
authors.lastname: Quinn
authors.forename: M
authors.initials: M
authors.lastname: Traub
authors.forename: C D
authors.initials: CD
authors.lastname: Marsden
mesh_terms: D000328:Adult; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007441:Intubation, Gastrointestinal / Q000295:instrumentation; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D011597:Psychomotor Performance / Q000187:drug effects
chemical_list: D015259:Dopamine Agents; D010078:Oxazines; C042631:naxagolide; D007980:Levodopa